Compare QDEL & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | QDEL | CTMX |
|---|---|---|
| Founded | 1979 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 977.1M |
| IPO Year | 2022 | 2015 |
| Metric | QDEL | CTMX |
|---|---|---|
| Price | $11.37 | $3.77 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 10 |
| Target Price | ★ $28.25 | $12.10 |
| AVG Volume (30 Days) | 3.0M | ★ 3.1M |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 45.35 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,730,200,000.00 | $76,201,000.00 |
| Revenue This Year | $3.51 | N/A |
| Revenue Next Year | $3.86 | $7.61 |
| P/E Ratio | ★ N/A | $22.58 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.92 | $1.72 |
| 52 Week High | $35.58 | $8.21 |
| Indicator | QDEL | CTMX |
|---|---|---|
| Relative Strength Index (RSI) | 42.11 | 34.05 |
| Support Level | $10.86 | $3.76 |
| Resistance Level | $12.85 | $3.91 |
| Average True Range (ATR) | 0.92 | 0.22 |
| MACD | 0.17 | -0.03 |
| Stochastic Oscillator | 51.88 | 9.87 |
QuidelOrtho Corp is engaged in the development, manufacturing, and marketing of rapid diagnostic testing solutions. The company is engaged in immunoassay and molecular testing, clinical chemistry, and transfusion medicine, which helps clinicians and patients to make decisions across the globe. Geographically, the company has its presence in North America, EMEA, China, and Other countries. It generates the majority of its revenue from North America.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.